Stocksigma LogoStocksigma Logo

Aurobindo Pharma Secures USFDA Approval for First Complex MDI Inhaler

Aurobindo Pharma received USFDA final approval on 15th Sep'26 for Beclomethasone Dipropionate HFA Inhalation Aerosol (40 mcg and 80 mcg), a generic

Aurobindo Pharma Secures USFDA Approval for First Complex MDI Inhaler

Aurobindo Pharma Ltd 路 Press Release 路 15 Sept 2026, 6:40 pm

Aurobindo Pharma Secures USFDA Approval for First Complex MDI Inhaler Aurobindo Pharma received USFDA final approval on 15th Sep'26 for Beclomethasone Dipropionate HFA Inhalation Aerosol (40 mcg and 80 mcg), a generic equivalent of Teva鈥檚 QVAR. Marking Aurobindo鈥檚 first metered-dose inhaler product, it will be manufactured at subsidiary Aurolife Pharma's North Carolina facility with launches slated for upcoming quarters. According to IQVIA, the relevant US market was valued at US$301 million for the 12 months ended Jul'26. This expands Aurobindo's cumulative USFDA ANDA portfolio to 596 approvals (571 final, 25 tentative).

Original exchange filing (PDF)

More announcements from Aurobindo Pharma Ltd

All Aurobindo Pharma Ltd announcements